Mark A. Hull
Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial
Hull, Mark A.; Sprange, Kirsty; Hepburn, Trish; Tan, Wei; Shafayat, Aisha; Rees, Colin J.; Clifford, Gayle; Logan, Richard F.; Loadman, Paul M; Williams, Elizabeth A; Whitham, Diane; Montgomery, Alan A.; seAFOod Collaborative Group
Authors
KIRSTY SPRANGE Kirsty.Sprange@nottingham.ac.uk
Assistant Professor
TRISH HEPBURN Trish.Hepburn@nottingham.ac.uk
Senior Medical Statistician
Wei Tan
AISHA SHAFAYAT Aisha.Shafayat@nottingham.ac.uk
Research Facilitation Manager
Colin J. Rees
Gayle Clifford
Richard F. Logan
Paul M Loadman
Elizabeth A Williams
Diane Whitham
ALAN MONTGOMERY ALAN.MONTGOMERY@NOTTINGHAM.AC.UK
Director, nottingham Clinical Trials Unit
seAFOod Collaborative Group
Abstract
© 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
Background
The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) and aspirin both have proof of concept for colorectal cancer chemoprevention, aligned with an excellent safety profile. Therefore, we aimed to test the efficacy of EPA and aspirin, alone and in combination and compared with a placebo, in individuals with sporadic colorectal neoplasia detected at colonoscopy.
Methods
In a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial, patients aged 55–73 years who were identified during colonoscopy as being at high risk in the English Bowel Cancer Screening Programme (BCSP; ≥3 adenomas if at least one was ≥10 mm in diameter or ≥5 adenomas if these were
Citation
Hull, M. A., Sprange, K., Hepburn, T., Tan, W., Shafayat, A., Rees, C. J., …seAFOod Collaborative Group. (2018). Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial. Lancet, 392(10164), 2583-2594. https://doi.org/10.1016/S0140-6736%2818%2931775-6
Journal Article Type | Article |
---|---|
Acceptance Date | Nov 19, 2018 |
Online Publication Date | Nov 19, 2018 |
Publication Date | Nov 19, 2018 |
Deposit Date | Nov 21, 2018 |
Publicly Available Date | Nov 22, 2018 |
Journal | Lancet |
Print ISSN | 0140-6736 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
DOI | https://doi.org/10.1016/s0140-6736%2818%2931775-6 |
Keywords | General Medicine |
Public URL | https://nottingham-repository.worktribe.com/output/1297453 |
Publisher URL | https://www.sciencedirect.com/science/article/pii/S0140673618317756?via%3Dihub |
Files
Eicosapentaenoic acid and aspirin
(390 Kb)
PDF